Mathias Kaas Ollendorff

Charles River Discovery Research Services Finland Oy provides non-clinical central nervous system services to the pharmaceutical and biotechnology industries. The company was founded in 1998 and is located in Kuopio, Finland.

Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom.

Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland.

Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014.

Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland.

Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020.

Part of University of Helsinki, Helsinki Innovation Services Ltd. is a company that provides business and innovation-related consulting services. The company is based in Helsinki, Finland.

Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020.